Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer Clinical Trial

Official title:

A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ® ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00066729
• Other study ID #: CDR0000318803
• Secondary ID: MSKCC-03034LUD20
• Status: Completed
• Phase: Phase 1
• Start date: June 23, 2003
• Est. completion date: August 1, 2013

Study information

• Verified date: October 2023
• Source: Ludwig Institute for Cancer Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: A phase I trial to study the side effects of vaccine therapy in patients with ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Description:

OBJECTIVES:

• Determine the safety of NY-ESO-1b peptide vaccine and Montanide® ISA-51 in patients with ovarian epithelial, primary peritoneal, or fallopian tube cancer.

• Determine the immunologic profile (NY-ESO-1 antibody, CD8+ cells, and delayed-type hypersensitivity) induced by this regimen in these patients.

OUTLINE: This is an open-label study.

Patients receive NY-ESO-1b peptide vaccine emulsified with Montanide® ISA-51 subcutaneously once every 3 weeks on weeks 1, 4, 7, 10, and 13 in the absence of disease progression or unacceptable toxicity.

Patients are followed at 3 weeks (week 16) and then every 6-12 weeks for 2 years or until disease progression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: August 1, 2013
• Est. primary completion date: May 9, 2006
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Histologically documented epithelial carcinoma arising in the ovary, fallopian tube, or peritoneum, from Stage II-IV at diagnosis, receiving initial cytoreductive surgery and chemotherapy with at least one platinum-based chemotherapy regimen.

2. High risk feature defined as suboptimal primary debulking (remaining tumor masses with diameter = 1.0 cm) or failure to normalize CA125 during primary therapy by the end of the third cycle or positive second-look surgery.

3. Patients must be in complete clinical remission defined as CA125 < 35 units, negative physical examination and no definite evidence of disease by computed tomography (CT) of the abdomen and pelvis. Lymph nodes and/or soft tissue abnormalities = 1.0 cm that are often present in the pelvis may not be considered definite evidence of disease.

4. Expected survival of at least 6 months.

5. Karnofsky performance scale =60%.

6. Within the last 2 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified:

• Absolute neutrophil count (ANC) =1000/mm^3

• Platelets = 80,000/mm^3

• Creatinine = 1.5mg/dL

• Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), and total bilirubin all < 2.5 x upper limit of normal (ULN) 7 Age = 18 years.

8. Able and willing to give valid written informed consent. 9. HLA A02 positive. Exclusion Criteria

Patients were excluded from the study for any of the following reasons:

1. Clinically significant heart disease (NYHA Class III or IV).

2. Other serious illnesses, e.g., serious infections requiring antibiotics or bleeding disorders.

3. Patients with serious intercurrent illness, requiring hospitalization.

4. Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.

5. Patients taking immunosuppressive drugs such as systemic corticosteroids or non-steroidal anti-inflammatory drugs.

6. Known HIV positivity.

7. Other malignancy within 3 years prior to entry into the study, except for treated nonmelanoma skin cancer and cervical carcinoma in situ.

8. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.

9. Lack of availability for immunological and clinical follow-up assessments.

10. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.

11. Pregnancy or breastfeeding.

12. Women of childbearing potential: Refusal or inability to use effective means of contraception.

Related Conditions & MeSH terms

• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Ovarian Cancer
• Primary Peritoneal Cavity Cancer

Intervention

Biological:
• NY-ESO-1 peptide vaccine
NY-ESO-1b peptide 100 µg mixed with 0.5 mL of Montanide® ISA-51

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Ludwig Institute for Cancer Research	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, Iasonos A, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epi — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Dose Limiting Toxicities (DLTs)	Toxicities and adverse events defined by National Cancer Institute Common Toxicity Criteria (CTC) Scale (Version 2.0, published April 30, 1999). DLT defined as: = Grade 2 autoimmune phenomena, asymptomatic bronchospasm or generalized urticaria, or = Grade 3 hematological and non hematological toxicities. To be dose-limiting, an adverse event must be definitely, probably, or possibly related to the administration of the investigational agent.	up to 16 weeks
Secondary	Number of Patients Developing NY-ESO-1 Antibodies After Treatment	Blood samples were obtained at baseline and in weeks 4, 7, 10, 13 and 16 for the assessment of NY-ESO-1 specific antibodies by enzyme-linked immunosorbent assay (ELISA).	up to 16 weeks
Secondary	Number of Patients With NY-ESO-1b-Specific CD8+ T Cells Measured by Tetramer Analysis	Blood samples were obtained at baseline and at 4, 7, 10. 13 and 16 weeks. Tetramer assays were conducted after presensitization of CD8+ T cells with NY-ESO-1b. Results are presented separately for patients with NY-ESO-1 positive and negative tumors.	up to 16 weeks.
Secondary	Number of Patients With NY-ESO-1b-Specific Activated CD8+ T Cells Measured by ELISPOT	Blood samples were obtained at baseline and at 4, 7, 10, 13 and 16 weeks. T cell responses were monitored after the in vitro sensitization with NY-ESO-1b (157-165), modified NY-ESO-1b-A (157-165A), or control peptide influenza matrix 58 to 66. Results are presented separately for patients with NY-ESO-1 positive and negative tumors.	up to 16 weeks
Secondary	Number of Patients With NY-ESO-1b-specific Delayed-type Hypersensitivity (DTH)	NY-ESO-1b-specific delayed-type hypersensitivity (DTH) was measured by number of patients with induration and/or redness at each timepoint.; NY-ESO-1b-specific DTH skin reaction was measured at baseline and weeks 7 and 16. The NY-ESO-1b peptide solution (0.1 mg/mL in 8% DMSO) was injected intradermally at a separate site from the vaccination to give a visable and palpable skin depot. The extent and intensity of DTH reactions were documented by measuring visible redness, palpable induration and other signs of local skin irritation or necrosis. Assessment of DTH reaction was performed 48 hours after injection, and the diameter of the reaction was documented.	up to 16 weeks